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1. Introduction 
 
Health care expenses are steadily increasing since the 60’s. Advances in technology and treatment 
options have broadened since then, and life expectancy has risen substantially in the industrialised 
world.  
Formerly rapidly fatal diseases like leukaemia and lymphoma are today treatable illnesses with the 
hope of long-term survival. 
The usual treatment options for haemato-oncological diseases now include high dose 
chemiotherapy and bone marrow transplantation. These very aggressive treatments are not without 
important side effects, some of them life-threatening. 
Systemic fungal infections are one of these feared complications. Treatment options for serious 
infections in the immunocompromised host are still very limited and not free from additional side 
effects.  
A new generation of antifungal drugs recently entered the market with a lower side effect profile 
but also a much higher cost. In Switzerland the new liposomal Amphotericines did not obtain 
authorisation for reimbursement by health insurance companies, and if prescribed, are paid entirely 
by the hospital budget.  
This particular situation, like many similar others, occurs at a time when hospital budgets are limited 
and not extensible any more. Therefore, choices need to be made on how to allocate these rare 
resources. 
At our University Hospital, global budget put a major constraint on all departments and services. In 
this context, it happened that the division of infectious diseases experienced for several years 
important deficits in their drug budget, due to the use of systemic antifungal drugs. 
Agreeing with the recommendation of federal authorities, new diagnostic and therapeutic 
procedures have to undergo a medical and economic evaluation process in our institution.  
For this purpose, a cost-effectiveness analysis has been performed, in order to establish a valid 
policy about the use of available antifungal drugs.  
The extraordinary price difference between the two drug formulations is not compensated by a 
difference in efficiency, but is justified by the pharmaceutical industry mainly because of a different 
side effect profile. Modulation of the incidence of side effects of the old drug was recently shown to 
be possible 
The discussions we had with the medical and nursing team during the cost-effectiveness evaluation 
showed that they had clear drug preferences. We were therefore interested in investigating the 
problem of drug preferences and their impact on drug choices.  
The best-established method for this purpose is the contingent valuation method, which uses the 
willingness to pay to elicit preferences in monetary terms. This economically sound method has 
been used mainly in areas others than health care, due to the obvious difficulty to value health in 
monetary terms. Despite this ancestral reticence, this method is attracting growing interest in the 
actual financial health care crisis. 
In a pilot study we used the willingness to pay method to show the possibilities and limits of this 
method as a tool for evaluating educated preferences of health care professionals. 
This study will, after an introductory part, present both the cost-effectiveness analysis and the cost-
benefit analysis, which was based on the results of the previous study.  
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1.1 Local conditions 
The University Hospital of Lausanne has a triple mission: it is a regional hospital for the city of 
Lausanne and a population of 300’000 inhabitants. It is also a secondary centre for the whole 
Canton including approximately 600’000 inhabitants; and it is a tertiary centre and a teaching 
hospital for the French speaking part of Switzerland for several health care professions, including 
doctors, nurses, physiotherapists, laboratory technicians and others (1). 
This broad mission is reflected in the size of the hospital and its staff and equipment. (Annexe 1). 
The almost 800 beds show constantly a very high occupancy, especially in the medical specialties. 
(Annexe 2) 
 
1.1.2 Hospital data 
The 4000 employees of the hospital are state employees. The university hospital is the biggest 
employer in the canton and includes a great variety of professions. Employees from more than 100 
different nations are working in the institutions. The turnover can be very high in some sectors, for 
example in the nursing field. Medical residents have very often a short-term contract for training, 
which explains the high rotation rate amongst them. 
 
1.1.3 Hospital budget  
The hospital budget is a fixed state subsidy of approximately about 50 % of the expenses, the other 
50% being covered by the insurance companies. Every division has its own fixed envelope for 
running costs. 
The pharmacy budget is likewise allocated to each division, service or department. It is important to 
mention, that neither the hospital administrative data, not the medical records do allow, to identify a 
single patient’s drug consumption and expenses.  
 
1.1.4 Haematological oncological diseases 
The incidence of acute lymphoblastic and myeloblastic leukaemia is about 5-6 cases per 100’000 
inhabitants per year. The disease consists in a monoclonal proliferation of early bone marrow cells 
with consequently disturbed production of all blood components. Patients are diagnosed very often 
with a bleeding disorder and an infection and are severely ill at admission. The immediate treatment 
of a newly diagnosed leukaemia is a medical emergency. The induction treatment aims at reducing 
the number of leukaemic cells and restoring the normal blood functions (2). After the induction 
treatment, according to the response to the first line therapy, patients receive another cycle of high 
dose chemotherapy, which is, in some indications, followed by bone marrow transplantation. The 
whole treatment from diagnosis to consolidation therapy can take as long as 2 years and sometimes 
even longer. 
 
1.1.5 Complications during the treatment of hematological malignancies 
The treatment of acute leukaemia is frequently associated with complications. The incidence of 
minor complications, like digestive disorders, anaemia and low grade fever are higher than 60%. 
Severe complications occur mainly during the phase of neutropenia. The risk increases in 
proportion with the length of neutropenia, which is in the case of acute leukaemia up to 20-30 days. 
High grade fever occurs in about 40% of the cases (2). The underlying cause is therefore extensively 
investigated, but the bacterial or fungal origin can be clearly diagnosed only in a small proportion of 
cases.  
 
 
1.1.6 Leukemia treatment in the Infectious Diseases Unit 
 
The Infectious Diseases Division is an isolation unit for respiratory, infectious or high risk diseases 
requiring isolation of the patient. Each of 13 single rooms is equipped with laminar flow and sas. 
The medical staff on this  ward is composed of 2 residents, 16.1 FTE nurses and 3.9 FTE nursing 
aids. 
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Patients with haematological malignancies are the biggest patient population in this unit, with the 
longest hospital stay (Table 1). 
Due to this particular patient population, the unit has developed a strong interrelationship with the 
division of Haematology. Patients are followed by both divisions on a regular basis. The residents 
are supervised by a senior fellow and by an attending doctor of both specialties. 
 
Table 1 
The Infectious Disease Unit 
 1996 1997 1998 1999 
Number of patients 241 223 259 256 
Number of hospitalisation days 4’200 4’296 4’552 4’785 
Occupancy (%) 82.0 84.1 89.1 93.6 
Medium length of stay ( days) 17.4 19.3 17.6 18.7 
Number of Patients in isolation 
(protective) 
202 176 194 188 
Patients with hematological 
malignancies 
 131 158 146 
from which 
• high dose chemiotherapy with 
autologous BMT 
• from Geneva 
• for leucopheresis 
 
 
 
 
35 
 
13 
0 
 
40 
 
19 
9 
 
41 
 
15 
5 
Patients with solid tumours  42 36 36 
Number of hospitalisation days 3’706 3’874 3’760 3’880 
Medium length of stay( days) 14.8 11.12 14.83 18.56 
Patients hosted from the Department of 
Internal Medicine 
13 11 35 45 
Number of hospitalisation days 107 55 364 441 
Medium length of stay (days) 8.2 5 10.4 9.8 
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2. Cost-Effectiveness analysis 
 
Cost-effectiveness analysis is the most widely used pharmacoeconomic analysis in the medical 
literature. It compares clinical efficacy and costs of different alternative strategies. Because all cost 
effectiveness analyses are comparative, the cost and clinical outcome of health care technology must 
be compared to those associated with an alternative strategy for treating the same group of patients.  
 
2.1 Aim of the study 
In this study, we foresee to establish the cost and effectiveness of all available treatment options in 
case of suspected or diagnosed disseminated fungal infections in patients with neutropenic fever not 
responsive to broad-spectrum antibiotics, after high dose chemotherapy for leukaemia with or 
without autologous bone marrow transplantation.  
 
2.2 Methods 
 
2.2.1 Effectiveness measurements 
• Description of available treatment options and their side effects. 
• Literature review with the elements to define the effectiveness of the drugs in the case of 
suspected or proven fungal infection in the neutropenic host. 
• A ten years review of the leukaemia patients in the CHUV (3,4) 
 
2.2.2 Cost analysis 
• The cost analysis takes the standpoint of the hospital finances.  
• We determine the drug budget for the institution and different departments  
• Main cost analysis is based on the acquisition costs of all available drugs. 
• The analysis focuses on direct cost and is not considering indirect costs or intangible costs 
 
2.3 Sensitivity analysis 
 
2.3.1 Simulation of one drug costs 
• Simulation of financial impact of one drug use on the drug budget  
 
2.3.2 Simulation of variation in patient population 
• Financial impact of increasing patient population on the drug budget  
 
2.3.3 Data sources 
• Medical literature is available through the hospital electronic library (medline). 
• Medical records are taken into account in the 10 year analysis. 
• Hospital pharmacy for drug data.  
• Administrative data for admission and discharge data and diagnostic codes as well as the overall 
consumption of diagnostic tests and costs of care (nursing and physiotherapy, etc.). 
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3. Results 
 
3.1 Literature review 
 
Patients undergoing high dose chemotherapy experience a period of neutropenia and profoundly 
reduced immune functions. During this period they are at risk of developing any kind of infectious 
complications. The risk increases with the length of neutropenia and presents with fever, which is 
treated readily with broad spectrum antibiotics A fungal infection occurs in about 30 % of patients 
in neutropenia the mortality reaches 40-80% (5). The most common fungal infections are due to 
Candida albicans, the most invasive to Aspergillus fumigatus. Unfortunately, it is difficult to 
cultivate and isolate these infectious agents. In most of the cases the presumed diagnosis is based 
on a strong clinical suspicion. The treatment of fungal infections in neutropenic patients is therefore 
a real challenge for physicians. 
In the following analysis we will use the commercial names for clarity purpose in distinguishing 
between the three formulations of Amphotericine. 
 
3.1.1 Available drugs 
Fungizone is the treatment of choice in suspected and proven systemic fungal infections since 
almost 40 years. The standard dose of Fungizone (0.6-1.25mg/kg/d) is administered over a 4-6 
hour period. It is very a well established drug despite the fact that the majority of patients (79%) 
experience reactions while receiving the drug (6) from which 44% are due to Fungizone. 
 
Abelcet is the first drug of the new generation of Amphotericins. It is described as a lipid complex. 
The appropriate dose varies between 3mg/kg/d and 5mg/kg/d given over several hours. No 
definite evidence in the literature favours either the higher or the lower dose. Abelcet has been 
extensively studied during the past decade. 
Ambisome was the last drug to enter the market and is the only drug which is a true liposomal 
formulation. Many comparative studies with Fungizone have been undertaken mainly to compare 
their toxicities. The usual dose of Ambisome varies between 1mg/kg to 5mg/kg. The most used 
dosage is 3mg/kg. (6,7). 
3.1.2 Effectivness  
Effectiveness measures in antibiotic resistant neutropenic fever can be defined as: 
• Survival of treatment and discharge alive 
• Fever reduction despite neutropenia 
• Absence of breakthrough fungal infections 
 
The definition of effectiveness in the empirical treatment of febrile neutropenia is already a difficult 
task. Effectiveness indicators used in the literature are very different from each other and cannot be 
directly compared. A comparative study (8) between Fungizone and Ambisome showed a success 
rate of 50,1% for Ambisome and 49,4% for Fungizone. Fever reduction and reversed neutropenia 
were observed in both treatment groups in 58% of the cases. 
The absence of systemic fungal infections could be confirmed in 90% of the cases; 85,7% of the 
patients could continue their treatment without delays in the Ambisome group and 81,4% in the 
Fungizone group.  
Based on this study and others not to in this analysis, it can be concluded that both drugs can be 
considered as equally effective in treating suspected fungal infections in febrile neutropenic patients.  
 
3.1.3 Toxicity 
The toxicity can be measured in general symptoms and organ specific toxicities: 
• Acute, infusion related toxicity, general symptoms (Chills, fever) 
• Organ specific toxicity (Nephrotoxicity)  
• Treatment interruption for toxic reasons 
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• Treatment switch for toxic side effects 
 
As toxicity is the major criterion distinguishing the three drugs, a separate description will be 
provided of this aspect has been made for clarity.  
The toxicity in the original and liposomal forms is essentially acute or perfusion related. It consists 
in chills, fever, hypotension, nausea and vomiting in decreasing order of frequency. These acute 
reactions abate for unknown reasons over the treatment course. Increasing with the length of 
treatment is nephrotoxicity, which is not perceived by the patient. 
Fungizone treatment causes acute perfusion related side effects in 79% of the cases (renal function 
impairment) from which 44% are due to the drug (6). Hypotension might occur and mandates vital 
signs to be controlled frequently during the perfusion (9). Elevated creatinine levels are observed in 
different ranges in 50-80 % of the patients (8). This effect is dose related and occurs mainly after the 
15th treatment day, or after a cumulative dose of 2000mg of Fungizone. 
The renal toxicity is in general transient and reversible after stopping the drug administration. Only 
6% of the patients presented a severe renal failure, if several pre-existing renal risk factors 
associated (other nephrotoxic drugs like cisplatine, and cyclosporine or pre-treatment renal 
impairment) (9). Renal acidosis and important potassium loss can complicate the treatment with 
Fungizone in 38% of the cases (10). Acute as well as cumulative side effects can be controlled up to 
a certain degree with an adequate premedication and hydration. 
An important reduction of all side effects seems possible by extending the infusion time from 4 
hours to 24 hours, as recently shown (11). This randomised study compared the acute and 
cumulative side effects in 67 patients. Patients receiving the 24 hours perfusion presented 
significantly less toxic side effects such as shivering (p=0.0006), and vomiting (p=0.0037). The 
perfusion or the treatment was significantly less often interrupted (p=0.0001) in the 24 hours 
infusion group. The 4 hours infusion group presented more frequently renal impairment, defined as 
a reduction of 25% in the creatinine clearance. 
Abelcet has a small rate of minor effects, like chills, tachycardia and fever (6). Some rare cases of 
severe bronchospasms were described (12). At the usual doses the nephrotoxic effect was mild.  
Ambisome is known for its low acute and cumulative toxicity. Infusion related fever occurs only in 
9% of the cases, and only in case of high dosage (5mg/kg/d) (13). 
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3.2 Ten years review of antifungal drug use and outcome in the Infectious 
Disease Unit 
 
A recent poster presented by A.K. Lapointe (4) reviewed the last ten years of antifungal treatment in 
the isolation unit. Table 2 shows the patient characteristics during this period. This table confirms 
that the great majority of patients who developed neutropenic episodes and were at risk for 
developing infectious complications were suffering from acute leukaemia. High dose chemotherapy 
led to the greatest risk for fungal infections.  
 
Table 2 
Patient characteristics of 861 non-allo BMT neutropenic episodes in adult cancer patients 
studied over the period 1990-1999 
 
Patients treated with Amphotericine  130  
Age (years; median, range) 53 (17-78) 
Underlying malignancy   
 Acute leukaemia 107 (82%) 
 Lymphoma 12 (9%) 
 Others 11 (9%) 
Neutropenic episodes treated with Amphotericine  163  
 Myeloablative chemotherapy 143 (88%) 
 Auto-BMT 14 (8%) 
 No chemotherapy 6 (4%) 
Duration of neutropenia (days; median, range) 26 (5-84) 
 .K.Lapointe et al, ICAAC 2000 
 
Table 3 shows the number of patients treated during a period of 10 years and the treatment 
indication. 
The majority of treatment indications (54%) were fever of unknown origin in a neutropenic patient 
(empiric indication). It represented 44 % of all treatment days. Aspergillosis, a very severe fungal 
infection, represented 25% of all episodes but 32% of the treatment days.  
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Table 3 
Indications for Amphotericine treatment 
 
 
Indication Treatment episodes 
(%) 
Treatment days 
(%) 
Treatment days 
Median (range) 
Total dosis 
(mg/kg) 
Median (range) 
Empiric 89 (54) 1027 (44) 9 (2-52) 6 (1-36) 
Candidiasisa 24 (15) 438 (19) 16.5 (4-66) 12.5 (3-68) 
Aspergillosisb 40 (25) 740 (32) 15.5 (2-85) 11.5 (1-126) 
Othersc 10 (6) 128 (5) 12 (4-33) 8.5 (2-28) 
All 163 (100) 2333 (100) 11 (2-85) 7 (1-126) 
A.K.Lapointe et al, ICAAC 2000 
 
a 10 possible, 14 proven. b 27 possible, 5 probable, 8 proven. c 3 Invasive fungal infection (IFI), 7 suspected 
IFI not confirmed in follow-up. Treatment duration and total dosis for both most frequent IFI, candidiasis 
and aspergillosis, were significantly different from those of empiric treatment  : p<0.05 and p<0.0001, 
respectively. 
 
During the last 10 years the vast majority of patients were treated as first line therapy with 
Fungizone. It needs to be taken into account that the new antifungal drugs were only used very 
sporadically before 1996. This fact is reflected by the very low percentage of patients treated with 
the liposomal drugs (Table 4). 
 
Table 4 
Treatment days with the different forms of Amphotericine for the different indications 
Empiric Invasive fungal 
infections 
All 
Drugs   (%) 
Fungizone 634 (90%) 850 (77%) 1’484 (82%) 
Abelcet 13 (2%) 160 (14%) 173 (9%) 
Ambisome 57 (8%) 102 (9%) 159 (9%) 
TOTAL 704 (100%) 1’112 (100%) 1’816 (100%) 
A.K.Lapointe et al, ICAAC 2000 
 
This 10 year review also showed the side effects experienced by the 193 treatment episodes in table 
5. It showed likewise that 26% of all Fungizone treatment episodes needed to be interrupted for 
toxic reasons. 
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Table 5 
Treatment side effects (%) with the different forms of Amphotericine for the different 
indications 
 
 
Side effects Fungizone Abelcet AmBisome 
Treatment episodes (total 193) (n=159) (n=17) (n=17) 
Nephrotoxicity  85 (53)  2 (12)t  1 (6) t 
 moderate  54 (34)a  2 (12)  1 (6) 
 severe  31 (19) a  0   0  
 stop of treatment c  26 (16)  0   0  
 residual  3/77 (4)  0   0  
Chills and fever  107 (67)  11 (65)  5 (29) t 
 stop of treatment c  10 (6)  2 (12)  1 (6) 
Hypokaliemia  107 (67)  11 (65)b  7 (41)b 
 moderate  54 (34)  4 (24)  5 (29) 
 severe  53 (33)  7 (41)  2 (12) 
 stop of treatment c  2 (1)  0   0  
Renal acidosis  26/76 (34)  4/13 (31)  1/9 (11) 
 stop of treatment c  2 (1)  0   0  
Bronchospasm  3 (2)  1 (6)  0  
 stop of treatment c  1 (1)  1 (6)  0  
Overall stop of treatment  41 (26)  3 (18)  1 (6) t 
   A.K.Lapointe et al, ICAAC 2000 
 
t
 : P<0.06 if compared to Fungizone. 
a : Concomitant nephrotoxic drugs were administered in 23/54 (43%) of episodes of moderate and in 12/31 
(42%) of episodes of severe nephrotoxicity. 
b : Due to Rx with Fungizone, hypokaliemia was already present before switch to Abelcet or Ambisome, 
respectively, in 7/17 and 11/17 episodes. 
c : During neutropenia. 
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Table 6 
Patient outcome after treatment with Fungizone 
 
 Empiric Treatment 
(%) 
Invasive fungal 
infection (%) 
Survival at discharge  72/75a (96)  50/57b (88) 
Clinical response  49/72 (68)  41/57c (72) 
Patient who remained on 
Fungizone throughout Rx 
 54/75 (72)  35/57 (61) 
Success  36/72 (50)  29/57 (51) 
 A.K.Lapointe et al, ICAAC 2000 
 
a : 3 deaths. 1 Pt had autopsy : upper gastrointestinal hemorrhage (cause of death) and macroscopic 
oesophageal candidiasis (possible fungal breakthrough). The others 2 deaths were due to : encephalitis of 
unknown origin, intracranial hemorrhage (Invasive fungal infection not excluded in these 2 episodes). 
b : 7 deaths. Autopsy performed in 5 Pt identified a fungal cause of death (cerebral Aspergillosis, Mucor 
pneumonia, pulmonary Aspergillosis, disseminated fusariosis, disseminated Aspergillosis). The remaining 
2 deaths were possibly due to an Invasive fungal infection (pulmonary Aspergillosis). 
c : 16 failures: 7 deaths (see comment d), 9 non responses (2 of which in uncontrolled underlying 
malignancies) :1 documented Pseudoallescheria boydli, 4 proven Candiasis, 2 probable Aspergillosis, 2 
possible Aspergillosis. 
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3.3 Cost analysis 
 
The cost analysis is focusing only on direct costs and does not include indirect costs or intangible 
costs. The hospital standpoint is taken in account.  
 
3.3.1 Drug budget 
As briefly mentioned in the introduction, drugs have a special status in the hospital finances.  
Table 7 and 8 show the evolution of the drug budget of our institution in relation to the infectious 
disease division. 
It is at this point in time impossible to identify the drug cost of an individual patient unless the 
medical record is taken in account for every single patient. It would be very important be able to 
establish a cost per patient analysis. The attempt to do so has been made but did not lead to a 
reliable result without a system of analytical accounting.  
 
Two considerations can be made even in the absence of our own data. The literature reports that 
the side effects due to Fungizone treatment do not increase the hospital stay. Our preliminary data 
show that the nursing workload (in PRN points) does not increase significantly for patients 
experiencing major complications.  
 
Table 7 shows the drug budget for the institution over the last two 2 years. It also shows the actual 
expenses and the two-year variation. This budget is compared to the drug budget of the infectious 
disease unit and its actual expenses.  
Table 7 
Drug budget and actual expenses CHUV and Infectious disease division 
 1998 
 
1999 
 
Variation 
1998/1999 
Budget  13'096’700 13'329'412 232’712 
actual expenses 13'853’914 14'374'583 520’669 
∆ 757’314 1'045’171 287’857 
Infectious disease 
Haematology-Oncology 
(ID+HO) 
ID HO ID HO ID HO 
Budget 501’150   278’500 502'600  325’000 1’450 46’500 
actual (ID+HO) 534’089    324’745 663'070 331’150 128’981 6’405 
∆ 32’939/ 46’245 160’470 6’150 127’531 40’095 
Budget ID + HO 779’650 827’600 47’950 
actual ID + HO 858’834 994’219 135’385 
∆ 79’184- 166’619- 87’435 
Percentage budget 
CHUV/ 
ID+HO 
Actual ID+HO 
 
5,9% budget  
 
6,2% actual budget  
 
6,2% budget  
 
6,9 % actual budget 
 
∆ Percentage of budget 
CHUV 
10,5% 16,0 % +5,5% 
 
Table 8 shows the drug expenses per patient in relation to the number of hospitalisation days and 
the number of hospitalised patients in different departments and divisions. 
 
To evaluate the impact of very expensive drugs on the hospital drug budget, we established a drug 
cost per hospitalisation day for the whole institution and specifically for certain departments 
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considered to be heavy drug consumers, like the department of medicine and surgery and their 
specific intensive care divisions. We used actual drug costs, not the budgeted sum. 
 
 
Table 8 
Drug costs per hospitalisation day and per patient during 1999 
 
1999 Number of 
patients 
Hospitalis. 
days 
Actual drug 
expenses 
1999 
Drugs 
expenses per 
hospitalis. day 
Drugs 
expenses/ 
patient 
CHUV 
 
26’860 274’727 14'374’583 53,32 535,16 
Infectious disease** 256 4’785 994’219 207,77 3'883,66 
Internal medicine B 2’104 18’900 570’655 30,19 271,22 
General Surgery  2’762 26’214 1'013’999 36,81 367,24 
Medical Int. Care  999 5’014 1'017’739 202,85 1’018,75 
Surgical intensive 
care/Burn Unit 
1’383 5’666 1'086’269 191,71 785,44 
**Included Haemato-oncology 
 
This table shows quite impressively that the isolation unit has by far the highest drug expenses per 
patient compared to any other department of our institution.  
 
 
3.3.2 Antifungal therapy 
The costs of intravenous antifungal drugs were established with data from the central pharmacy. 
Costs are acquisition prices for our pharmacy and do not necessarily correspond to market prices. 
The three drugs evaluated in the literature are considered here for cost analysis. We did not consider 
drugs which are currently under investigation or which cannot be considered as standard treatment. 
 
 
3.3.3 Cost analysis of anti fungal drugs 
Table 9 shows the drug acquisition costs per patient treatment day and per department. 
It is easy to see that the difference in acquisition cost between the three drugs is 10 to 30 times the 
costs of original drug.  
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Table 9 
Antifungal drug acquisition cost per unit of weight and per dosage and per average patient  
 
Drug Dosage Cost per unit/kg Cost per patient per 70kg 
Fungizone 0,6 mg 0.408 Sfr 28.56 Sfr 
 1,0 mg 0.68 Sfr 47.60 Sfr 
Abelcet 1 mg 2.19 Sfr 153.30 Sfr 
 3 mg 6.57 Sfr 459.90 Sfr 
 5 mg 10.95 Sfr 766.50 Sfr 
Ambisome 1mg 6.03 Sfr 422.10 Sfr 
 3mg 18.09 Sfr 1’266.30 Sfr 
 5mg 30.15 Sfr 2’110.50 Sfr 
 
 
The following table 10 shows the total antifungal drug use in 1999 in the hospital. It highlights the 
fact that, intravenous antifungal drugs are used only in specialised departments. (Data provided 
from the hospital pharmacy).  
 
 
Table 10 
Acquisition costs of the different formulations of Amphotericine available in 1999 
 
1999 Fungizone Abelcet Ambisome Total 
Infectious Disease Unit 9’659 61’709 63’599 134’967 
Department of Medicine     
Intensive Care 2’818 8’815 15’003 26 636 
Hospitalisation Internal Medicine  1’083 4’410  5 493 
Department of Surgery     
Intensive care 418 11’024 6’445 17 887 
Hospitalisation  Surgery 2’809 2’203  5 012 
Department of Paediatrics     
Intensive care and hospitalisation 2’227 4’410  6 637 
Total 1999 18’255 66’108 78’621 196’632 
 
 
Mémoire 07.02.2006 18/48 
3.3.4 Disease related drug costs 
The three treatment indications for systemic antifungal drugs cover very different disease severity 
and treatment duration. The mere drug acquisition costs vary therefore very much according to the 
disease, the drug choice and dosage. Table 11 shows that the cost of an empirical treatment of 
neutropenic fever vary about 30 fold. As shown in our 10 year review, at least 54% of all treatments 
with antifungal drugs were started empirically. 
Table 11 
Disease related drug costs  
 
  Cost per patient 
per treatment day  
(average )  
Aspergillosis 
dissiminated 
Candidosis  
dissiminated 
Empirical 
treatment  
Drug 
Formulation 
Dosage Cost per 
average patient, 
weight 70 kg 
Cost of  
26,3 day 
treatment (Sfr) 
Cost of 
17,day 
treatment 
(Sfr) 
Cost of 
9,4 day 
treatment 
(Sfr) 
Fungizone 0,6 mg  28.56  751.12  502.56  268.46 
 1,0 mg*  47.60  1’251.80  837.76  447.44 
Abelcet 1 mg  153.30  4’031.79  2’698.08  1’441.02 
 3 mg*  459.90  12’095.70  8’094.24  4’323.06 
 5 mg  766.50  20’158.95  13’490.40  7’205.10 
Ambisome 1mg  422.10  11’101.23  7’428.96  3’967.74 
 3mg*  1’266.30  33’303.69  22’286.88  11’903.22 
 5mg  2’110.50  55’506.15  37’144.80  19’838.70 
* in black are the most frequently used dosages 
 
This table shows all dosages used in clinic and considered safe as and valuable treatment options. 
The dosage most frequently used is highlighted in black.  
It is clear that each treatment course using the expensive drug has an important impact on the 
division’s drug expenses The cost evolution over the last three years in the infectious disease 
department is shown in table 12. This evolution explains the vast majority of the drug deficit in this 
division. 
 
Table 12 
Costs of Antifungal drugs in the Infectious Disease Unit 
 
Infectious Disease Unit Cost evolution 1997-1999  
 
 Fungizone(
%) 
Abelcet 
(%) 
Ambisome 
(%) 
Total 
(100%) 
1997 10'044 
(33) 
2'156 
(7) 
17'850 
(60) 
30’050 
1998 10'082 
(14) 
37'235 
(50) 
27'132 
(36) 
74’449 
1999 9'659 
(7) 
61'709 
(46) 
63'599 
(47) 
134’967 
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Table 13 shows that in 1998 the expensive drugs were rarely used as empiric treatment but limited 
to disseminated fungal infections (non empiric). 
 
Table 13 
Annual cost of antifungal treatment (treatment days) 1998 
 Empiric 
(treatment days) 
 
Non empiric 
(treatment days) 
 
Total costs 
(treatment days) 
% of costs 
Fungizone 3’136  
(66) 
6’946 
(146) 
10’082 
(212) 
14% 
Abelcet 3’239 
(7) 
33’996 
(74) 
37’235 
(81) 
50% 
Ambisome 6’430  
(5) 
20’702  
(16) 
27’132 
(21) 
36% 
Total 12’805  
(78) 
61'644 
 (236) 
74’449  
(314) 
100% 
 
 
3.4. Sensitivity analysis 
 
The previous cost analysis could did show very clearly that the drug budget of the whole institution 
and particularly of the infectious disease unit is very sensitive to a rather small number of drug 
choices. 
 
3.4.1 Simulation of Drug costs in the infectious disease Unit 1999 
 
Treatment days for 1999 are not available but can be obtained indirectly through the drug expenses. 
The number of patients treated as well as the number of hospitalization days remained the same in 
1998 and 1999. The number of treatment days inferred from the drug expenses shows that the 
treatment days had increased from 314 to about 387 (+18%). The acquisition cost of antifungal 
drugs had increased during the same period likewise from 74’449 Sfr to 134’967 Sfr (+55%.) 
In table 14 we simulate the compulsory use of a single drug in the infectious disease unit during a 
one year period (data from 1999). The total Amphotericine cost can vary according to the drug 
choice significantly.  
 
Table 14  
Simulation of Drug costs in the infectious disease Unit 1999 
1999 Fungizone Abelcet Ambisome Total 
Real drug consumption 1999 9’659 61’709 63’599 134’967 
Presumable treatment days 203 134 50 387 
Fungizone only (387 days) 18’444   18’444 
Abelcet only (387 days)  177’981  177’981 
Ambisome only (387 days)   490’058 490’058 
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3.4.2 Simulation of the financial impact of increasing the size of the patient population 
The data from the Infectious Disease Unit showed that the patient population remained very stable 
over the last three years. It is however possible to envision an increase of patients referred for this 
very specialised treatment to our institution. 
In the following table we simulate the financial impact of increasing patient population by 5, 10 or 
20 per year.  
The 41 patients treated in 1999 for acute leukaemia received presumably 387 days of antifungal 
drugs or 9,3 days per patient. 
We did take into account that in the year 1999 antifungal treatment was given during 10% of the 
hospitalisation days for oncological diseases. We are unable to distinguish hospitalisation days of 
patients with acute leukaemia from those with other tumours as indicated in Table 1 The simulation 
is therefore potentially optimistic, as the complication rate of disseminated fungal infections is 
much lower for patients with solid tumours. 
 
Table 15 
Simulation of the financial impact of an increasing patient population  
 
1999 Number of 
patients 
Hospitalisatio
n 
days 
Hospitalisation 
days with 
antifungal 
drugs 
(%) 
Total Antifungal drug 
acquisition costs 1999 
(%of total drug budget 
 ID- HO) 
CHUV 26’860 274’727   
ID high dose 
chemotherapy patients  
146 3’880 387 
(10%) 
134'967 
(16%) 
Additional patients Patient 
number 
Total 
hospitalisation 
days  
Marginal drug 
expenses per  
additional 
patients ID-
HO 
 
Number of patients  
( 19 days, average 
hospitalisation days ) 
5 
(95) 
3’975 19'738 154'705 
 
 10 
(190) 
4’075 38'836 173'803 
 
 20 
(380) 
4’260 77'673 212'640 
 
 
A rather small increase in the patient population has immediate important consequences on the 
drug budget, growing by 10% with an increase of 20 patients.  
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4.0 Conclusion of the cost-effectiveness analysis 
 
Systemic fungal infections in febrile neutropenic patienst are still a feared complication with an 
important morbitiy and mortality. The three Amphotericine formulations evaluated previously 
have shown to be equally effective for the defined endpoint such as there are the survival at 
discharge, the absence of breakthrough fungal infections and the decrease of fever despite 
neutropenia. 
 
The main difference between the three drugs remains the acute and cumulative side effects of 
Fungizone. The recent study from Zürich showed that it was feasible to considerably reduce 
these side effects of Fungizone by increasing the infusion rate from 4 to 24 hours (11). This 
very simple measure may change the cost benefit ration if liposomial formulations.  
 
For our institution the conclusion from this analysis is that the liposomal formulations cannot 
be considered cost affective as first line therapy. However their use can be indicated and fully 
justified in case of Fungizone incompatibility or preexisting renal impairment. 
  
Our conclusion has been very recently confirmed by the International Society of Infectious 
Diseases, which published a full set of guidelines on the treatment of fungal infections (14-16). 
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4.1 Motivation to go further and develop a cost benefit analysis 
 
The previously described cost-effectiveness analysis showed the complexity of the medical and the 
economic situation, which has to be faced when very expensive drugs are required but not 
reimbursed by social security. 
 
Drug price negotiation could be one of the solutions in this financial dilemma or at least be part of 
it. In this particular case, drug prices were determined by pharmaceutical industry marketing policy. 
The original drug does not benefit from any kind of marketing effort any more as it has been on the 
market for almost 40 years. In the recent literature, hardly any study has been published using 
Fungizone as the investigational drug, except the study by Eriksson, modulating its side effects (11).  
 
The liposomal drugs benefit worldwide from a very aggressive marketing campaign in the first 5 to 
10 years after their registration in the USA, including a very restrictive price strategy. Therefore the 
price negotiation solution did not solve the financial problem. 
 
Budgets can only be kept if health care professionals are aware of costs and are motivated to 
acknowledge the budget constraint. This motivation is kept alive if their ‘educated’ preferences are 
taken into account and respected. 
In this particular situation the medical and economic importance of every single treatment choice 
motivated us to investigate individual preferences of health care professionals, in a cost-benefit 
analysis, using the willingness to pay method. During several discussions we had realized that 
professionals expressed very clear preferences, which we wanted to know and understand better.  
 
The review of the literature showed that only very few studies addressed the problem of preferences 
of health care providers (17), which gave us the chance to perform a pilot study on willingness to 
pay also for the first time in our institution.  
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5.0 Cost benefit analysis 
 
5.1 The Theoretical Foundations of cost-benefit analysis  
 
The welfare theory is the economic theoretical background of the cost benefit analysis (CBA). 
Welfare economics is a branch of economics that addresses normative questions because it 
embodies certain value judgements in contrast to most of economic evaluations, which make 
predictions without value judgements.  
The principal value theory has been developed by V. Pareto in the nineteenth century. He assumed 
that individuals are the best judges of their own welfare (18). This theory describes that the benefit 
an individual derives from a service or an intervention is defined as his or her maximum willingness 
to pay for this service or intervention. The benefit of the intervention for the society is the sum of 
each individual’s willingness to pay.  
 
In the presence of budget constraints, CBA may allow decision makers to rank the net benefits per 
unit of budget expenditure for all possible interventions, and use this ranking to allocate the limited 
budget among competing expenditures. Income effects can likewise be taken in account and 
smoothen social differences  
 
Since then, three different approaches have been developed within the cost benefit analyses, the 
human capital approach, the revealed preference studies and the contingent valuation method. We 
will focus in this analysis exclusively on the contingent valuation analysis or willingness to pay 
method. 
 
 
5.2 Cost-benefit analysis in health care 
 
Cost-benefit analysis (CBA) expresses all costs and benefits (or consequences) in monetary terms. 
As money is a universal good, health care programs can therefore be compared to programs in 
other economic areas. It also allows resource allocation in health care to be finally compared to 
other economic sectors.  
The great perceived disadvantage of this particular approach in the field of health care is the fact 
that human lives and quality of life as well as medical ethics need to be expressed in monetary units 
(19). This explains why the cost-benefit approach has been used so little by health care professionals 
in the past. Mainly physicians find it difficult and even unethical to translate intrinsic medical values 
into money.  
The term cost-benefit analysis has been widely used in the medical literature probably because of 
ethymologic reasons, but often inappropriately. It has been shown that 53% of the studies labeled 
as cost-benefit analysis were only cost-comparison analysis. Only 13% of the studies performed 
between 1991-1995 used the contingent valuation method and could be labeled rightly cost-benefit 
analysis. (20-22). 
A 10 year review of the literature showed that the contingent valuation method was the most 
frequently used analysis amongst the different forms of cost-benefit analysis. The described studies 
are all small and very often do not go beyond the phase of a pilot study. However the literature 
shows that the contingent valuation method is a valid method in health care. Studies focusing on 
cost-benefit analysis of entire health care programs are very rare (23-28).  
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5.3 The contingent valuation method or ‘Willingness to Pay’ (WTP) 
 
5.3.1. Description of the model 
 
The contingent valuation method is a survey based method using hypothetical scenarios to 
determine monetary valuations of effects of health technologies and benefits (22). 
Respondents are asked to think about the contingency of an actual ‘market’ for a health care 
program and to state the maximum they are willing to pay out of their own pocket to have the 
program or benefit. They are asked to consider their real financial possibilities when answering the 
bidding questions. The method implies that the consumer is willing to give up other activities or 
services to obtain the health service. In a way, the WTP analysis is trying to create a market situation 
where there normally is none.  
The validity of the results of this method depends strongly on the choice of the area to be 
investigated and the way the scenarios are built. A very important aspect is the wording and the 
language used in the scenarios. In the following sections we will outline the different key aspects of 
the contingent valuation method.  
 
5.3.2 The scenario and the questions 
 
The contingent valuation scenarios describe a hypothetical situation and ask the respondent to 
situate himself/herself in that given situation for the duration of the questionnaire. The scenario has 
to give the necessary aspects and details of the health program to allow the respondent to determine 
his or her WTP in the scenario question. Direct and indirect questions are possible. Direct 
questions are the simplest method to ask individuals for their WTP. In this case the respondent has 
to identify himself his own WTP without any reference amount. This method requires a strenuous 
effort from the respondent and might lead to quit especially if the motivation to answer the 
questions is not enhanced by other means. 
A higher participation can be obtained with the use of payment cards, which indicate a range of 
predetermined amounts from which the respondent has to choose one. 
The WTP survey can be performed as a telephone interview, a direct interview, a computer based 
system or a mail survey. The cost of the survey varies considerably according to the method chosen, 
the most expensive being the computer based and the individual method. The mail survey is used 
frequently but risks a rather low response rate. 
Every aspect of the contingent valuation scenarios is important and carries the potential for biases.  
 
5.3.3 Potential Biases 
The contingent valuation method allows a number of method-specific biases, which might 
jeopardise the validity of the method and need special consideration (29, 30). 
 
1. Implied value cues represent a bias when information is contained in the contingent 
valuation scenarios, which implies a certain value for the good. An important and well- 
known example of the implied value cue bias is the starting point bias. This implies that 
the WTP can be influenced by the value of the first bid offered, such that a higher starting 
bid determines a higher WTP. The payment card system offering a range of monetary 
values, can be source of starting point bias as well as range bias due to the chosen bidding 
interval. 
 
2. Scenario misspecification occurs frequently, when respondents do not answer correctly 
the contingent valuation question, often because the question is asked incorrectly. 
 
3. A third category of biases might occur if the respondents have an incentive to 
misrepresent responses and to state their WTP a higher or a lower than what they would 
have given as the real value. This bias could occur if the privacy of the respondents is not 
protected or, if the results of the study is directly used by decision making authorities.  
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4. The hypothetical nature of the scenario might represent a bias. Studies showed that the 
hypothetical WTP is in general significantly overestimated compared to the real WTP. 
Calibration methods to reduce or to eliminate these biases are currently developed (31). 
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6.0 Pilot study to elicit educated preferences from health care professionals for high 
cost antifungal drugs 
 
6.1 The aim  
This study aims at eliciting drug preferences of health care professionals for high cost antifungal 
drugs in the same setting as described in the cost-effectiveness analysis. We wanted to assess their 
WTP in relation to the previous study and understand whether their preferences agree with the 
conclusion of the cost-effectiveness analysis. Our aim is also to assess the value given to drug side 
effects. 
Preferences and value statements might differ according to the level of specific knowledge and 
training. We foresee to elicit preferences from trained health care professionals and consider them 
as ‘educated’ preferences. A group of non medically trained health care professionals is included as 
general population (29).  
 
This first pilot study in our institution was also for us the beginning of the methodological 
validation process of the contingent valuation method in health care. It gave us a preliminary view 
of the method its limits and possibilities. It would allow us also to gain a first experience with the 
potential biases, known to be linked to this method.  
 
 
 
6.2 The hypothesis 
It becomes more and more important to allocate scarce resources according to the real value of a 
treatment or of a service. Educated preferences and value statements from professionals and 
instructed lay person could be considered close to the real value of a health good if expressed 
appropriately. These educated preference statements could participate in the decision making 
process, on a local level as well as on a bigger scale. They could also indicate whether administrative 
decisions are supported by professional values. 
 
The study population were doctors and nurses from the division of infectious diseases and from the 
general internal medicine ward. The general population was represented by social workers and 
nursing aids. We chose this study population because of their specific knowledge in this special 
setting and because they potentially express preferences from slightly different standpoints. 
 
We suppose that doctors in charge of these high-risk patients would express their preferences in 
full knowledge of the consequences. The fact that we asked for their personal preferences, if the 
disease affected themselves, might alter the answers. We expected them to be willing to pay for the 
new drug up to the real value of the drug. 
 
Nurses are in contact with a patient on a daily basis in a very privileged way. They are very sensitive 
to patients complaints and well-being. Their profession makes them take care of any complaints at 
first, before the doctor. 
The nursing profession is essentially based on the present medical situation of a patient. A 
prospective view of the disease and the evaluation of long-term risks are not necessarily taken in 
account by the nurses. This point of view might influence the value nurses give to the new drug and 
its benefits, in a way that they express a certain WTP for the new drugs.  
 
The choice of the general population was made for practical as well as policy reasons. 
Nursing aids have in general no professional training in the medical field. They are informed at the 
beginning of their activity and mainly trained on the job. No specific knowledge on the disease or 
on its outcome can be expected from them. Their main task is to help the qualified nurses in basic 
nursing, like assistance in personal hygiene and feeding. This allows the nursing aid to have a very 
intimate contact with patients, without necessarily understanding entirely the medical condition. We 
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expected nursing aids to hesitate in the bidding process, giving importance to the new treatment but 
not entirely. They might present some problems in understanding the questions. 
 
Social workers are very in very close contact to the different functions and professions in the 
hospital. Without a specific training in the medical field, they are for many aspects the link between 
the patient and the different medical professions. They are aware of the patient’s personal and 
financial situation as well as the possibility to obtain additional subsidies. Social workers feel 
strongly about the patients needs, but they do understand the possibilities and limits of the financial 
resources in society.  
We expect social workers to give importance to the new treatment. 
 
We did not include patients in this preliminary study. The main reason was the critical situation in 
which these patients are once they are hospitalised. In addition, a research protocol needs to be 
approved by the ethical committee to include presently affected patients or former patients.  
 
 
6.2.1 The scenarios 
 
An introduction letter described the method and the aim of the study to the respondents assuring 
complete confidentiality. Three scenarios described likely situations in the infectious disease 
division. The respondent was requested to consider suffering from leukaemia for the duration of 
the study and answering the following questions:  
 
Scenario 1:  
 How much are you willing to pay to avoid the risk of a major complication ? 
   
 
Scenario 2:  
 Thank you for indicating us how much you are willing to pay put of your own 
 pocket for the drug, which gives less side effects ( for a complete treatment course 
 of at least 10 days ) 
 
Scenario 3: 
 How much are you willing to pay out of your pocket for the new drug if we reduce 
 the side effects of the original drug by half (for a complete treatment course ) ? 
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6.2.2 The bidding   
We used a payment card system with 9 increasing and decreasing ranges randomly allocated to 
each professional category. The bidding interval had been selected between nothing and more than 
32’000Sfr. Using doubling steps allowed a wide range of possible willingness to pay.  
 
Bidding ranges in Swiss Francs 
 
Nothing 
0-499 
500-999 
1’000-1’999 
2'000-3'999 
4'000-7'999 
8'000-15999 
16'000-31'999 
more than 32'000 
Blank 
 
 
6.2.3 The difficulty 
An evaluation of the perceived difficulty was requested with the following answer possibilities : 
 
1. was difficult to answer the question 
2. was difficult to understand the question 
3. was difficult to determine the WTP 
4. was or was not a pertinent question 
5. was easy to answer the questions 
 
6.2.4 Demographic data  
Personal data concerning the age, the profession and the health insurance status as well as the 
respondents own health status were recorded. A question about the family members health status 
was included to evaluate the influence of personal experience with oncological diseases.  
 
6.2.5 Data analysis 
In this preliminary study we will limit our data analysis to descriptive statistics. A further 
econometric evaluation will be performed. 
 
6.2.6 The review process and the motivation sessions 
The internal validation process through peer review was considered important in a pilot study using 
a new method in our institution. Prior to the study the preliminary questionnaires were sent for 
internal peer review and authorisation.  
Pre-study information sessions were organised for all 4 professional categories. The aim of the 
study was either directly explained to the respondent by the physician investigator (doctors and 
social workers) or indirectly through a senior staff member (nurses). The original questionnaire can 
be found in annexe 3. The study process is resumed in table 14. 
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Table 16 
Process : Establishing a questionnaire using the contingent valuation method 
 
Is the informal preference  consistent with a
hypothetical WTP ?
Development of three hypothetical scenario's  to
evaluate WTP in selected health care
professionals
Critical review of the scenario's by senior staff
physicians
Formal permission obtained from the head of the
departments and divisions
Information and motivation session : Prior to
distribution of questionnaires
Physician investigator informed
and motivared physicians
Physician investigator
informed head nurse
Physician investigator informed head of social
workers
Head nurse informed nurses
and nursing assistants on
volontary participations
Staff social worker informed  the  team
Questionnaire's sent back to physician
investigator in preformatted envelops
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7.0 Results: 
 
7.1 Personal characteristics of respondents  
 
We included 153 health care professionals. We obtained 97 answers, from which 1 invalid answer 
and 4 protest answers, which were excluded from the statistical evaluation.  
 
Table 17 
Personal characteristics of respondents 
 
Frequency 
 
N % 
 
96 100 
Gender   
male 32 33 
female 64 67 
Age : mean (range) 34,5  (20-61)  
 
 
 
Profession 
 
 
Resident 12 12,5 
Junior Staff 10 10.0 
Senior Staff 8 8.0 
Social worker 11 11,4 
Registered nurse 34 34,4 
Staff nurse 10 10,4 
Nursing aide 11 11,4 
Total 96 
 
 
 
 
Country of origin   
Switzerland 58 60 
Europe 25 26 
America/Canada 11 11 
Missing data 2 2 
 96 100 
  
 
Insurance status   
Basic package 54 56 
Private insurance 40 42 
Missing data 2 2 
 96 100 
  
 
Health Status   
Perfect 95-100% 71 74 
Slightly reduced 80-94% 25 26 
Moderately reduced 70-79%  0 0 
Seriously reduced < 70 0 0 
  100 
   
Household income 
 (before tax) average  
50’000-100’000  
   
Family status   
Live alone 38 41 
Live in couple or married 32 34 
Live with children and or married 21 23 
Live with parents 2 2 
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Despite thorough information and motivation sessions, varied the response rates amongst 
professions very much as it is outlined in table18. Due to the rather low response rate of physicians 
it was impossible to evaluate separately the staff from the infectious disease unit. It was likewise 
impossible to distinguish the response rate of the registered nurses, the staff nurses and the nursing 
assistants as they all received the same envelope. The very high response rate amongst the nursing 
profession could be explained by their work in a team, compared to the more individualistic 
approach of physicians.  
 
Table18 
Response rate of different professions 
 
Response rate  
Profession No. responses  % 
Residents 12 24% 
Junior Staff 10 59% 
Senior Staff 8 43% 
Social worker 11 55% 
Registered nurse  34  
Staff nurse 10 80% 
Nursing aide 11  
Overall response rate  96 61% 
 
Table 19 shows the response rate in relation to the questionnaires. We only received one invalid 
answer and 4 protest answers with some missing data. Other questionnaires had hand written 
comments, which will be resumed in table 20 
  
Table 19 
Response rate and questionnaires 
 
Number of questionnaires 
 
 
Sent 157  
Response  97 Response rate 62% 
Invalid 1  
Protest answers 4 Protest answers : 4 % 
Valid questionnaires 96  
Questionnaire   
Top down  32'000-0 Sfr. 53 55% 
Bottom up 0-32'000 Sfr. 43 45% 
 96 100% 
 
The personal comments in table 20 reflect the difficulty of the willingness to pay method in health 
care. They confirmed the importance of broad and thorough information about the method and its 
potential goals as well as its limitations.  
These pertinent comments are an expression of the suspicion health care professionals express 
when monetary values are put on health issues.  
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Table 20 
Personal comments of the respondents concerning the willingness to pay means  
 
1. This approach leads to a two class medicine 
2. The questionnaire seems to be a bad marketing strategy 
3. It is unacceptable to estimate cost of life 
4. Fear about the use of the study results 
5. Health is not a merchandise 
6. Life does not have a monetary value 
 
 
 
7.2 Scenario results  
 
The evaluation of the scenarios will be analysed at first for the entire study population and 
subsequently by other variables like profession, health state and perceived difficulty.  
 
7.2.1 Total population Willingness to pay 
Table 21 shows the median WTP for the three scenarios. The 9 bids on our payment card can be 
divided into different categories: The clear expression of a ‘non WTP’ (1), the moderate WTP of up 
to 1’000 Sfr. (2 and 3) and high WTP (4 and 5) and the very high WTP (6-9). Table 21 shows the 
number of respondents for each bid and the cumulative percentage (in brackets). The total median 
WTP shows that the first scenario is valued very highly, the second moderately and the third 
expresses clearly the non-WTP for a new drug which differs only in some side effects from the 
original drug. 
 
Table 21 
Total population Willingness to pay 
Distribution of answers and cumulative percentage 
 
Bidding 
 ranges 
WTP 
Swiss francs 
Scenario 1 
(cumulative%) 
Scenario 2 
(cumulative %) 
Scenario 3 
(cumulative%) 
1 Nothing 19  
(21) 
28 
(30) 
46 
(50) 
2 0-499 1 
(22) 
13 
(45) 
12 
(63) 
3 500-999 5 
(27) 
12 
(58) 
4 
(67) 
4 1’000-1’999 2 
(29) 
8 
(68) 
5 
(73) 
5 2'000-3'999 7 
(37) 
7 
(74) 
14 
(88) 
6 4'000-7'999 12 
(50) 
13 
(88) 
3 
(91) 
7 8'000-15999 17 
(68) 
8 
(97) 
5 
(97) 
8 16'000-31'999 10 
(79) 
1 
(98) 
1 
(98) 
9 more than 32'000 19 
(100) 
2 
(100) 
2 
(100) 
0 Blank 4 4 4 
 96 96 96 
TOTAL Median WTP 4’000-7’999 500-999 nothing 
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7.2.2 Professional status and WTP 
 
We evaluated whether there were differences amongst professionals in the WTP. Table 22 shows 
that scenario 1 is valued highly by all professional groups participating in the study. Professional 
differences can be seen mainly for scenario 1. To explain the differences professional and economic 
aspects need further to be taken into account.  
 
Physicians value very highly the first scenario, because they understand that the absence or 
presence of an infectious complication represents the major risk reduction. The willingness to pay 
for the scenario 2 in which side effects play the major role is valued rather modestly by 
knowledgeable physicians in the department of internal medicine. Their willingness to pay for a 
treatment episode is only 10% of the drug cost. The scenario 3 in which the side effects of the old 
drug have been attenuated have clearly no willingness to pay.  
 
Nurses WTP showed the same trend as physicians. They valued highly the risk of complication and 
moderately side effects. The difference in monetary value needs a closer evaluation in relation to 
salary and working experience.  
 
The general population or social workers and nursing assistants repeated the same pattern in 
WTP as nurses and physicians, except for scenario 3 for which they expressed a WTP in the low 
range. It is very difficult for non-medically trained professionals to evaluate the importance of 
specific side effects and their consequences. The expressed WTP of 0-499 Sfr. for both scenarios 2 
and 3 reflects the difficulty to give a clear value of the side effects. We presume that some 
uncertainty is due to the lack of specific knowledge. 
 
Table 22 
Professional differences in willingness to pay  
 
Profession Scenario 1 
 
Scenario 2 
 
Scenario 3 
 
WTP for Risk of 
complication  
Side effects Comfort and some 
side effects 
Physicians 
N=30 
16’000-31’999 1’000-1’999 Nothing 
Nurses 
N=44 
2’000-3’999 0-499 Nothing 
Social workers/nursing aid 
N=22 
2’000-3’999 0-499 0-499 
Median WTP 
Total N=96 
4’000-7’999 500-999 nothing 
 
 
 
 
7.2.3 Salary adjusted willingness to pay  
 
The contingent valuation method asks the WTP from the own pocket. It is therefore important to 
evaluate an income adjusted WTP, which is outlined in table adjustment for income is important, it 
is outlined in table 21. 
The average working experience amongst professionals was quite uniform, but with a large standard 
deviation. No valid analysis can therefore be made about the impact of working experience. A 
subdivision in more homogeneous groups would be too small to be significant. 
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Table 23 
Willingness to pay as percentage of average salary 
 
Professions Scenario 1 
 
Scenario 2 Scenario 3 
Physicians 32% 2% 0% 
Nurses 7% 0,8% 0% 
Social workers/ 
Nursing assistants 
7% 0,8 % 0,8% 
Average % 
salary 
 
15,3% 1,2% 0% 
 
 
7.2.4 The starting point bias 
The payment card system used in our study required the evaluation of a potential starting point bias. 
In table 24 the WTP of our study population is evaluated in correspondence to the value of the first 
bid on the questionnaire. 
 
In scenario 1 the difference in WTP is of two ranges or by 4’000- to 12’000 Sfr. The questionnaires 
with the highest bid on the top of the payment card system had a two range higher WTP than those 
respondents who answered the low starting range. This observation is valid for all three scenarios 
but is the highest for the first scenario with a difference of 4’000-12’000Sfr. amongst the two 
scenarios. 
 
Table 24 
Evaluation of starting point bias 
 
 Scenario 1 
 
Scenario 2 Scenario 3 
WTP TOTAL 
POPULATION 
N=96 
4’000-7'999 Sfr 500-999 Sfr Nothing 
Questionnaire Bottom up 
 
N=43 
Top down 
 
N=53 
Bottom up 
 
N=43 
Top 
down 
N=53 
Bottom up 
 
N=43 
Top down 
 
N=53 
SFR 0-32’000  32’000-0  0-32’000  32’000-0 0-32’000 32’000-0 
 
Median WTP 
 
 
2’000-3’999 
 
8’000-15’999 
 
0-499 
 
500-999 
 
Nothing 
 
0-499 
∆ 
4’000-12’000 0-499 0-499 
 
 
7.2.5 The influence of the insurance status on the willingness to pay for expensive drugs  
The possible impact of insurance status on the WTP was investigated. The distribution of insurance 
status by profession is shown in table 25. It shows also that the insurance status is evenly distributed 
amongst the professions and represents about 50% basic insurance and 50% private insurance. 
Amongst the registered nurses the percentage of private insurance is the lowest, they present also 
the youngest group with the shortest professional experience. 
 
The median willingness to pay of the whole study population has been compared to the two 
insurance groups and showed no difference in willingness to pay between the two insurance states.  
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Table 25  
Insurance status by profession  
 
 Total Basic insurance package 
(%of population ) 
Private insurance 
(%of population) 
Total n=96    
Physicians 
 
30 16 
(53) 
14 
(47) 
Nurses 42 27 
(64) 
15 
(36) 
Nursing assistant/ 
social worker 
22 11 
(50)  
11 
(50) 
 
 
 
7.2.6 The influence of own health status and family member health status in the 
determination of WTP 
 
The impact of personal experience with altered health status on the willingness to pay for an 
expensive drug was taken into account in the following tables. We will distinguish the WTP of 
respondents with a perfect health status and those with a slightly diminished health. Respondents 
declaring to have at least one family member suffering from cancer will be taken into account 
separately, and in a second approach jointly. 
 
Table 26 
Respondents declared health status 
 
Health Status 
 
Number of 
respondents 
% 
Perfect (95-100%) 81 84 
Slightly reduced ( 80-94%) 12 12 
Moderately reduced (70-79% ) 0 0 
Seriously reduced (< 70%) 0 0 
Blank 3 4 
  100% 
 
We evaluated the WTP for respondents with a slightly reduced health status compared to the group 
in perfect health. We evaluated whether the impact of a personal physical impairment could 
possibly increase the willingness to pay. We tested this hypothesis by representing all respondents 
who had no willingness to pay for any of the three scenarios (n=17) according to their health state. 
Surprisingly 33% (n=4) of the respondents with some physical impairment had no WTP compared 
to 16% (n=13) of respondents in perfect health.  
 
We explored further the coincidence of the respondents own health status with the family health 
status. Only one respondent had a reduced health state and family members suffering from cancer. 
The 4 respondents with family members suffering from leukemia are likewise in perfect health. 
This fact allowed us to consider the family health status independently from the own health status 
in our study population. 
 
The median WTP for respondents with cancer patients in the family does not differ from the WTP 
of the general population. These results show that there seems to be little influence from personal 
and family experience on the WTP for a very specific treatment.  
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7.2.7 Evaluation of questionnaires 
 
The willingness to pay method was used for the first time in our institution and caused some 
surprise and difficulties for the respondents. We evaluated the difficulty to answer the scenario 
questions. Only 17% of the respondents thought that it was easy to answer the questions; 71% 
found it either difficult to answer the question or difficult to determine their willingness to pay. 
 
It is not surprising to find the majority of respondents had difficulties with the investigation tool. 
Table 27 shows the perceived difficulty with the scenarios, by professional category. Due to the 
rather small number of respondents by profession no significant difference could be detected. 
 
Tableau 27 
Difficulty for the different professions to answer the scenarios  
 
  Difficulty answering the scenarios 
 
  
Profession Blanc Yes to 
understand 
to determine 
WTP 
not 
pertinent 
Easy to 
answer 
Total 
population 
Physicians 
(%) 
0 
 
2 
(7) 
4 
(13) 
17 
(57) 
1 
(3) 
6 
(20) 
30 
Nurses 
(%) 
4 
(9) 
11 
(25) 
1 
(2) 
24 
(55) 
0 
(0) 
4 
(9) 
44 
Nursing 
assistants/soci
al workers 
 (%) 
1 
(5) 
4 
(18) 
1 
(5) 
10 
(45) 
0 
(0) 
6 
(27) 
22 
Total 
(%) 
5 
(5) 
17 
(18) 
6 
(6) 
51 
(53) 
1 
(1) 
16 
(17) 
96 
(100) 
 
 
How much the personal perception of the difficulties influenced the willingness to pay is evaluated. 
No difference in WTP could be detected between the respondent who found easy or difficult to 
answer the scenarios.  
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8.0 Conclusion: 
 
This study aimed at eliciting drug preferences from healthcare professionals for high cost antifungal 
drugs. This first cost-benefit analysis using the contingent valuation method in our institution 
included three groups of health care professionals (physicians, nurses, social workers) from the 
department of internal medicine and the division of infectious diseases. Three scenarios were given, 
asking for the willingness to pay for: a) a risk reduction (infectious complication ), b) a new drug 
with fewer side effects and c) a new drug if the side effects of the original drug had been reduced. 
 
We have reached an acceptable response rate of 61% for this unusual survey analysis in our 
institution. The influence of motivation sessions became very clear with a variation in response rate 
from 24% to 80%.  
 
The descriptive results showed that the respondents valued a) the risk reduction highly and b) the 
side effects moderately while c) there was no willingness to pay once the side effects were reduced 
for the original drug. Some professional differences in the willingness to pay can be attributed to 
professional knowledge.  
 
The salary adjusted median WTP showed that physicians valued the highest the total risk reduction 
for a complication (32% of their salary). For the other scenarios the difference between the three 
professional groups was just marginal. Other possible factors influencing the willingness to pay 
were evaluated to improve the method and understand potential biases.  
 
The literature on the contingent valuation method in health care mentions a number of potential 
biases, which represent an important aspect for its validity. In this study we addressed particular 
attention to these biases.  
 
The real value of the three different drugs can be easily obtained from health care professionals and 
can potentially represent an implied value cue bias. Some physicians are supposed to know the 
acquisition costs of the drugs, which is not the case for nursing aids and social workers. This might 
explain at least partly the observed difference. 
 
The importance of the first bid on the payment card on the WTP has been shown. The WTP was 
significantly higher in the group who had received the top down questionnaire. We could confirm 
the presence of a starting point bias in our study. The bias needs therefore to be addressed 
systematically in every study especially if the payment card system is used.  
 
Scenario misspecification is difficult to evaluate quantitatively if parameters are not clearly set at 
the moment of the study design. In our study we counted on the 4 protest answers, which were 
given because the respondents did not understand the goal of the hypothetical scenarios and they 
interpreted it exactly the contrary of what it was designed for. Misspecification is well expressed in 
the hand written comments resumed in table 20. This bias influenced our study by a maximum of 
10% of the respondents. 
 
In a further study this bias will need to be addressed systematically at the moment of the study 
design and a quantitative evaluation method of misspecification should be integrated in the study. 
Establishing a structured peer review prior to the study could allow reducing this bias considerably. 
The information and motivation sessions could participate in keeping the misspecification bias low. 
 
As the study was designed it seems difficult to imagine that employed health care professionals have 
a strong self-interest in stating their willingness to pay higher or lower than their real preferences. 
The possibility of an immediate impact of their WTP is not given in this study. We presume that 
this first pilot study was not incline to have a significant incentive bias to misrepresent the WTP.  
 
Mémoire 07.02.2006 38/48 
The hypothetical nature of the scenarios was a completely new experience for health care 
professionals. Overstatement or understatement of WTP could be possible but was not addressed 
in this study. This aspect of potential biases will need to be addressed in further studies using more 
sophisticated econometric analysis.  
 
Other potential influences were evaluated but did not, to our surprise, show significant differences; 
for example the insurance status and the personal and the family health status did not play a role 
in the WTP. These results need to be confirmed in a bigger study to validate the important result 
that the insurance status is independent from willingness to pay. 
 
One would also expect that close experience with a family member suffering from an oncological 
disease could motivate the respondent for a higher willingness to pay. This was not the case in our 
study. These results, of potential long-term importance, need to be confirmed through a multicentre 
study including actual, past and future patients.  
 
The validation question about the perceived difficulty to answer the questionnaires seemed to be 
essential at the end of the scenarios, because we could confirm the difficulty of this new tool for the 
population (80%) and we were able to specify the difficulties encountered. The determination of 
WTP presented for 53% of the respondents a hurdle. We understand hereby that only the careful 
preparation of the study population can keep them interested in this new approach.  
 
8.1 Did we meet the aims of our study ?  
 
We succeeded in conducting the first contingent valuation study in our institution with a significant 
response rate. We could elicit educated drug preferences from different professional backgrounds.  
The respondents expressed differentiated preferences and even if the question was directly asked, 
their preferences do not seem to be in contradiction with the conclusion of the cost effectiveness 
analysis. We obtained in scenario 2 a value given to side effects which can be compared to drug 
costs. 
 
We are satisfied with the participation of the nursing population and especially with the effort the 
nursing assistants had made to participate in the study (no missing data !)  
 
The methodological evaluation of the tool showed the number of potential and confirmed biases, 
which need further studies to validate the results. We can consider our first experience with this 
tool is a positive one.  
 
8.2 Limits of the performed pilot study 
The study design had a number of first evaluation problems. The study population chosen was 
appropriate but the motivation and information strategy not sufficient. The clarity of the 
questionnaires needs to be enhanced in further studies to reduce the number of respondents who 
declared that it was difficult for them to answer the question. 
 
A statistical and econometric evaluation needs to be established, allowing a far more detailed 
analysis of the results, which can increase the validity of the study and the tool. 
The first struggles with the database did not facilitate data analysis and need to be enhanced in a 
further study. 
 
8.3 Where to go from here ? 
 
We just experienced through this first pilot study the potential of a very powerful and important 
tool. The possibility to use a universal language (money) to express intrinsic human and health care 
values is a thrilling experience. We have to get more and more familiar with the instrument and its 
limitations to be able to use the results of the contingent valuation studies in many different areas.  
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In a rather small impact study we tried to understand whether the conclusions of the cost 
effectiveness study were supported by professionals, knowing that unsupported administrative 
decisions risk having little success. We could imagine motivating health care professionals to use the 
contingent valuation method as ‘loudspeaker’ of their preferences and intrinsic values. 
 
Decision makers on a local level as well as on a larger scale might benefit from this type of analysis. 
Cost-benefit analysis could be for example part of drug price negotiation and express educated 
preferences and value statements. 
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Annexe1 
Personnel in the CHUV 
 
 
 
 1998 1999 
Physicians  494.6  510 
Nurses  1’352.8  1'442.7 
Medical–technical staff  473.3  481.5 
Logistics  722.1  738 
Administratif   415.2  413.1 
Others  46.2  47.4 
Total  3’504.2  3'632.8 
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Annexe 2 
 
Number of beds and treatment days per division  
 
 
 
Beds and bed 
occupation 
Beds 
1998 
Median 
occ. 1998 
Beds 
1999 
Median 
Occ. 1999 
Medicine 278 93,2 267 95.8% 
Surgery 308 80,2 309 83.3% 
Gynecology and Obst. 72 64,1 72 74.5% 
Pediatrics 78 84,5 78 79.2% 
Total 734 84,0 726 86.6% 
 
 
 
Patient treated 1997 1998 1999 
Hospitalisations 25’206 25’670 25’840 
Semi hospitalisations 11’934 12’747 13’576 
Total 37’140 38’417 39’416 
 
 
 
Days 1997 1998 1999 
Hospitalisations 226’571 232’817 238’441 
Semi hospitalisations 11’934 13’333 14’402 
Total 238’505 246’150 252’843 
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Annexe 3  
WTP questionnaire 
 
  
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS 
 
 
Direction médicale 
 
CH-1011 Lausanne 
Tél. : 021 / 314 11 11 
 
Tél. direct :  021 / 314.18.02 
Télécopieur :  021 / 314.18.18 
 
 
 
 
 
 
 
Lausanne, le 7 février 2006 
 
Madame, Monsieur, 
Comme vous le savez, les budgets des hôpitaux sont limités et ne peuvent plus être augmentés. 
Nous nous trouvons donc toujours plus fréquemment dans des situations où nous devons faire 
des choix. Il est cependant primordial d’avoir des éléments objectifs et pertinents qui facilitent ces 
choix. 
Les professionnels de la santé comme vous sont les personnes les plus aptes à fournir ces 
éléments nécessaires pour prendre des décisions. Il est donc souhaitable que vous puissiez 
exprimer vos opinions et vos préférences. Cette étude a pour but de mettre en évidence la valeur 
que vous attribuez à un traitement particulier en tant que professionnel de la santé. Plus 
spécifiquement, nous vous présentons des situations concernant des traitements particulièrement 
chers et non remboursés par les caisses maladie. Pour cela, nous utilisons comme approche une 
technique appelée « méthode de contingence»  ou « willingness to pay», basée sur un 
questionnaire. 
Quelques questions personnelles et sur votre parcours professionnel complètent le questionnaire 
dans la mesure où ils peuvent influencer les réponses. 
Trois scénarios décrivent un certain risque associé à un état de santé. Nous aimerions savoir quelle 
valeur vous donnez à ce risque et combien vous seriez prêt(e)s à payer pour l’éviter. Nous vous 
demandons de cocher la somme maximale que vous envisagez de payer pour réduire le risque de 
maladie et ses conséquences. 
De manière à permettre d’affiner l’analyse des résultats, nous vous remercions vivement de 
répondre au plus près de votre conscience en tenant compte de vos ressources financières réelles. 
Les prix que nous vous indiquons sont des prix et des valeurs réels. 
Laissez-vous guider à travers ce questionnaire. Cela nous aidera à donner une réelle valeur à vos 
préférences. Nous assurons bien entendu la complète confidentialité de toutes les données. Les 
résultats seront analysés de manière à ne pas permettre d’identifier les participants à l’étude. Les 
résultats globaux vous seront fournis sur demande. 
Nous vous remercions de bien vouloir participer à cette étude. Votre contribution nous est 
précieuse. 
En restant à votre disposition pour tout renseignement que vous pourriez souhaiter, nous vous 
adressons, Madame, Monsieur, nos salutations les meilleures. 
 Dresse K. von Bremen Dr J.-B. Wasserfallen 
 Chef de clinique adjointe Adjoint au Directeur médical 
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SCENARIOS 
 
Scénario 1 
 
Considérez pour la durée de cette étude que vous avez une leucémie aiguë (sorte de cancer du sang). Vous 
savez que vos chances de survie durant les 5 prochaines années sont de 40% si vous êtes traité par 
chimiothérapie à haute dose. Vous savez également que le traitement intensif coûte cher (entre Sfr 60'000 
et Sfr 100'000). Ce traitement comporte un risque de complications mineures dans 60% des cas, et de 
complications sérieuses dans 30% des cas, chaque fois que vous êtes exposé à une chimiothérapie. Les 
complications sérieuses augmentent votre risque de décès de 50% dans les semaines suivantes. Si la 
complication est traitée avec succès, vos chances de survivre ne changent pas, c’est-à-dire que vous 
disposez toujours de 40% de chance les 5 prochaines années. 
 
Quelle somme seriez-vous d’accord de payer pour éviter le risque de complication majeure 
(maladie en plus de la leucémie) ? 
 
• Rien     
• 0-499 Sfr    
• 500-999 Sfr    
• 1’000-1’999 Sfr    
• 2’000-3’999 Sfr    
• 4’000-7’999 Sfr    
• 8’000-15’999 Sfr   
• 16’000-31’999 Sfr   
• plus de 32'000 Sfr   
 
 
Scénario 2 
 
Admettons que votre traitement de chimiothérapie à haute dose est compliqué par une infection fongique 
(à champignon) grave. Si elle n’est pas traitée, cette infection est fréquemment mortelle. Le traitement 
consiste en un traitement antibiotique intraveineux d’une durée d’au moins 10 jours. 
• Un seul médicament efficace existe pour traiter votre infection, mais sous deux formes 
pharmacologiques différentes. 
• Le médicament original est connu depuis 40 ans, et le deuxième est disponible seulement depuis 
quelques années. 
• Ces médicaments peuvent guérir votre infection dans plus de 60% des cas. Cela signifie que vous avez 
encore au maximum 40% de risque de mourir de votre infection. 
• Les deux médicaments sont égaux en efficacité, ce qui signifie que vos chances de survivre sont 
exactement les mêmes avec les deux médicaments.  
• La seule différence entre les deux médicaments est que l’original peut causer des effets secondaires. 
• Ces effets secondaires sont essentiellement de la fièvre, des frissons et des nausées lors des premières 
perfusions et une atteinte du fonctionnement du rein qui peut, dans quelques cas, nécessiter l’arrêt du 
traitement. Vous pourriez donc vous sentir encore moins bien. Les infirmières viendront plus souvent 
vous surveiller et prendre votre pression. 
• Le nouveau médicament donne nettement moins d’effets secondaires et vous aurez moins d’attention 
de la part des infirmières. 
• A la longue, il n’y a pas de différence majeure entre les médicaments : aussitôt que vous arrêtez de les 
prendre, les effets secondaires disparaissent. Vous n’aurez pas des complications à vie dues au 
médicament original. 
• La plus grande différence entre les deux médicaments est leur prix : Le médicament original est relativement bon 
marché et le nouveau beaucoup plus cher. 
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• Le médicament original est remboursé par votre caisse-maladie, contrairement au nouveau qui n’est 
pas remboursé, ce qui signifie que vous devez le payer de votre poche si vous le préférez. 
 
Merci d’indiquer quelle somme vous êtes d’accord de payer de votre poche pour avoir le 
médicament qui donne le moins d’effets secondaires ? 
(prix pour le traitement complet, au moins10 jours) 
 
• Rien     
• 0-499 Sfr    
• 500-999 Sfr    
• 1’000-1’999 Sfr    
• 2’000-3’999 Sfr    
• 4’000-7’999 Sfr    
• 8’000-15’999 Sfr   
• 16’000-31’999 Sfr   
• plus de 32'000 Sfr   
 
 
Scénario 3 
 
Maintenant, nous allons explorer une nouvelle situation. Vous présentez à nouveau une complication 
infectieuse suite à votre chimiothérapie à haute dose pour lutter contre la leucémie (comme dans le 
scénario nr 2). 
Des études récentes ont montré que les effets secondaires du médicament original peuvent être diminués 
si l’on change la durée d’administration. Si la durée de perfusion passe de 4 heures à 24 heures, cette 
simple mesure réduit la gravité des effets secondaires du médicament original de 50%, à moyen et à long 
terme. Cela signifie que vous pouvez encore subir quelques effets secondaires mais mineurs, dus au 
médicament original. 
Comme par cette nouvelle application nous avons pu changer les effets toxiques du médicament original, 
et qu’avec cette mesure les deux médicaments se ressemblent maintenant de plus en plus, nous aimerions à 
nouveau connaître vos préférences. 
 
Quelle somme êtes-vous d’accord de payer de votre poche pour le nouveau médicament si nous 
réduisons les effets secondaires de l’original de moitié ? 
(prix pour le traitement complet) 
 
• Rien     
• 0-499 Sfr    
• 500-999 Sfr    
• 1’000-1’999 Sfr    
• 2’000-3’999 Sfr    
• 4’000-7’999 Sfr    
• 8’000-15’999 Sfr   
• 16’000-31’999 Sfr   
• plus de 32'000 Sfr   
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5)  Avez-vous trouvé difficile de répondre aux questions des scénarios ? 
a)  oui          
si oui, pourquoi : 
I)  difficulté de comprendre les questions   
II)  difficulté de déterminer votre volonté de payer   
III) le sujet ne signifie rien pour vous      
 c) c’était facile de répondre aux questions      
 
 
 
MERCI BEAUCOUP D’AVOIR PRIS LE TEMPS DE REPONDRE A CES QUESTIONS 
 
 
Maintenant, nous souhaitons vous poser quelques questions personnelles et sur votre expérience 
professionnelle, puisque ces deux facteurs peuvent influencer vos réponses. Merci de bien vouloir y 
répondre aussi. 
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        Numéro ° Date  °  
Questionnaire  
 
1.1 Age       Sexe Femme   Homme  
 
1.2 Nombre d’années d’expérience professionnelle (années complètes)    
 
1.3 Pays d’origine :____________________________ 
 
1.4 Depuis combien d’années vivez-vous en Suisse ?      
 
1.5 Situation familiale :  
    a) Vit seul(e)    b) Marié(e) ou vit en couple   
   c) Vit avec des enfants   d) Vit avec des personnes plus âgées  
 
1.6 Quelle assurance avez-vous ? 
   a) Assurance de base        
 b) Assurance complémentaire/privée/semi privée    
 
1.7 Y a-t-il des membres de votre famille qui souffrent d’une leucémie ou un d’un  lymphome ? 
   a) oui      b) si oui, combien    
 c) non     
 
1.8 Y a-t-il des membres de votre famille qui présentent d’autres types de cancer? 
   a) oui      b) si oui, combien   
 c) non     
 
1.9 Comment jugez-vous votre état de santé actuel ? 
a)  parfait (95-100%)        
b)  légèrement compromis (80-94%)      
c)  modérément compromis (70-79%)      
d)  sérieusement compromis (< 70%)      
 
2.0 Avez-vous été hospitalisé(e) pour plus de 24 heures durant ces deux dernières  années ? 
   a) oui      b) si oui, combien de fois  
   c) non    
 
2.1 Quelle est votre profession ? 
  
 Médecin assistant(e)  Chef de clinique (CDCA)  Médecin cadre  
 Assistant(e) sociale  Infirmier(ière)  ICS / ICUS  
 Aide soignant(e)  
 
Questions pour les médecins 
 
2.2 Quel est votre secteur d’activité professionnelle actuel (plusieurs réponses possibles) ? 
 a) clinique   d) gestion de santé   
 b) recherche   e) politique de santé   
 c) enseignement  f) assurance    
 
2.3 Quels sont vos projets professionnels pour l’avenir ? 
 a) pratique privée  c) autres     
b) hôpital  
 
